Literature DB >> 15586225

Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number.

Shuichiro Sato1, Yuji Noguchi, Hisashi Wada, Shoichiro Fujita, Shinichiro Nakamura, Ryo Tanaka, Tetsuya Nakada, Kosei Hasegawa, Kazuhiko Nakagawa, Fumihito Koizumi, Toshiro Ono, Kazuhiro Nouso, Achim Jungbluth, Yao-Tseng Chen, Lloyd J Old, Yasushi Shiratori, Eiichi Nakayama.   

Abstract

We investigated NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and various types of cancer by quantitative real-time RT-PCR. In addition to their high expression in the testis, we observed a low expression of NY-ESO-1 mRNA in the placenta, pancreas and liver, and no expression in 12 other normal tissues. We also observed a low expression of LAGE-1a mRNA in the placenta and ovary, and marginal expression in 13 other normal tissues. In contrast to the previous finding that NY-ESO-1 and LAGE-1a mRNAs were mostly co-expressed in solid tumors, we found an independent expression of NY-ESO-1 and LAGE-1a mRNAs. NY-ESO-1 mRNA expression was mostly associated with LAGE-1a mRNA expression in esophageal and liver cancers, but not in prostate cancer. Immunohistochemistry (IHC) using NY-ESO-1-specific ES121 mAb showed that NY-ESO-1 protein was detected in 6 of 9 and 3 of 10 NY-ESO-1 mRNA-positive specimens from esophageal and liver cancers, respectively. NY-ESO-1 protein expression was correlated with the copy numbers of NY-ESO-1 mRNA. IHC was also performed using ES121 mAb and B9.8 mAb recognizing both NY-ESO-1 and LAGE-1a in 4 esophageal and 6 liver cancer specimens preferentially expressing LAGE-1a mRNA. B9.8-specific staining was observed weakly and focally in one liver cancer specimen expressing >10(5) copies of LAGE-1a mRNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15586225

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  The biology of cancer testis antigens: putative function, regulation and therapeutic potential.

Authors:  Elisabetta Fratta; Sandra Coral; Alessia Covre; Giulia Parisi; Francesca Colizzi; Riccardo Danielli; Hugues Jean Marie Nicolay; Luca Sigalotti; Michele Maio
Journal:  Mol Oncol       Date:  2011-02-18       Impact factor: 6.603

2.  Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma.

Authors:  Sun-Young Kong; Joong-Won Park; Jin Oak Kim; Nam Oak Lee; Jung An Lee; Kyung Woo Park; Eun Kyung Hong; Chang-Min Kim
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-31       Impact factor: 4.553

Review 3.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

4.  Immunotherapy for lung cancers.

Authors:  Ming-Yi Ho; Shye-Jye Tang; Kuang-Hui Sun; Winnie Yang
Journal:  J Biomed Biotechnol       Date:  2011-01-24

5.  Inducing multiple antibodies to treat squamous cell esophageal carcinoma.

Authors:  Isamu Hoshino; Yoshihiro Nabeya; Nobuhiro Takiguchi; Hisashi Gunji; Fumitaka Ishige; Yosuke Iwatate; Akiko Kuwajima; Fumiaki Shiratori; Rei Okada; Hideaki Shimada
Journal:  BMC Cancer       Date:  2020-10-17       Impact factor: 4.430

6.  Proficiency of nucleic acid tests for avian influenza viruses, Australasia.

Authors:  Sacha Stelzer-Braid; Ros Escott; Cristina Baleriola; Peter Kirkland; Peter Robertson; Michael Catton; William D Rawlinson
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

7.  Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

Authors:  Emmet McCormack; Katherine J Adams; Namir J Hassan; Akhil Kotian; Nikolai M Lissin; Malkit Sami; Maja Mujić; Tereza Osdal; Bjørn Tore Gjertsen; Deborah Baker; Alex S Powlesland; Milos Aleksic; Annelise Vuidepot; Olivier Morteau; Deborah H Sutton; Carl H June; Michael Kalos; Rebecca Ashfield; Bent K Jakobsen
Journal:  Cancer Immunol Immunother       Date:  2012-12-22       Impact factor: 6.968

8.  LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.

Authors:  Tina Chang Albershardt; David James Campbell; Andrea Jean Parsons; Megan Merrill Slough; Jan Ter Meulen; Peter Berglund
Journal:  Mol Ther Oncolytics       Date:  2016-03-30       Impact factor: 7.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.